Openfund

CORDIS · ACHILLES

Advancing in the CHallenge of Improving Lymphoma and LEukemia Survival

Код
ACHILLES
Програма
HORIZON
Процедура
MSCA Doctoral Networks 2024 HORIZON-MSCA-2024-DN-01-01
Статус
SIGNED
Период
01.12.2025 – 30.11.2029
Принос на ЕС (целият консорциум)4 251 589 €
Принос на ЕС за българските участници237 581 €

Официални данни · CORDIS · синхронизирано 17.10.2026 10:16 · официален запис

Участници

ОрганизацииРоляДържаваБезвъзмездна помощ
FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERASкоординаторES564 376 €
Lead Biologics International ABучастникSE324 630 €
KAROLINSKA INSTITUTETучастникSE324 630 €
UNIVERSITE PARIS CITEучастникFR314 669 €
STICHTING AMSTERDAM UMCучастникNL305 286 €
EBERHARD KARLS UNIVERSITAET TUEBINGENучастникDE290 272 €
ONECHAIN IMMUNOTHERAPEUTICS S.L.участникES282 188 €
UNIVERSIDAD COMPLUTENSE DE MADRIDучастникES282 188 €
UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCAучастникIT281 755 €
I3S - INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTOучастникPT279 445 €
ETHNIKO IDRYMA EREVNONучастникEL269 484 €
FARMACEUTSKI FAKULTET UNIVERZITETA U BEOGRADUучастникRS248 841 €
UNIVERSITATEA DE MEDICINA SI FARMACIE IULIU HATIEGANU CLUJ-NAPOCAучастникRO246 243 €
ИНСТИТУТ ПО МАТЕМАТИКА И ИНФОРМАТИКАучастникBG237 581 €
Pixelgen Technologies ABасоцииран партньорSE
Cobiomic Bioscience SLасоцииран партньорES
Fundació Internacional Josep Carrerasасоцииран партньорES
Sonja Nossасоцииран партньорDE
PANEPISTIMIO DYTIKIS ATTIKISасоцииран партньорEL
Saso Kocevarасоцииран партньорDE
Leadership Sculptor GmbHасоцииран партньорDE
SCIENSEED SLасоцииран партньорES
EUROPEAN HEMATOLOGY ASSOCIATIONасоцииран партньорNL
SPRINT BIOSCIENCE ABасоцииран партньорSE
STICHTING VUасоцииран партньорNL
European School of Haematologyасоцииран партньорFR
INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOLасоцииран партньорES
FUNDACIO CENTRE DE REGULACIO GENOMICAасоцииран партньорES
FUNDACIO PRIVADA PER A LA RECERCA I LA DOCENCIA SANT JOAN DE DEUасоцииран партньорES
UNIVERSIDADE DO PORTOасоцииран партньорPT
LUNDS UNIVERSITETасоцииран партньорSE
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICHасоцииран партньорCH
UNIVERSITAT DE BARCELONAасоцииран партньорES

Описание

ACHILLES is a Doctoral Network (DN) program designed to train the next generation of leaders in hemato-oncology, with a focus on the development of novel therapeutic solutions for hematological malignancies. The network brings together 14 institutions from 10 EU countries and one associated state, along with partners from the biotechnology and drug discovery sectors, including two European policy leaders in hematology, the European Hematology Association (EHA) and the European School of Hematology (ESH). Through this collaboration, ACHILLES will train 16 Doctoral Candidates (DCs) to develop essential skills in experimental hemato-oncology, including the design, development, and preclinical validation of innovative therapies.ACHILLES is structured around three key scientific objectives (SOs): (1) creating novel experimental models and analytical methods, (2) exploring the oncogenic mechanisms of hematologic malignancies, and (3) developing and validating new therapies, especially targeted treatments for leukemia and lymphoma. The program will integrate cutting-edge technologies such as AI, multi-omics, and computational modeling to push the boundaries of current research and therapy development. These innovations will be applied to generate better diagnostic tools, predict treatment responses, and optimize therapeutic strategies.With a patient-centered approach, ACHILLES aims to foster both academic and industrial collaboration, bridging gaps between scientific research and clinical application. This initiative aligns with the EU's Beating Cancer Plan, with a particular focus on improving survival rates and treatment accessibility, especially in Widening Countries. Through strong academic-industrial partnerships, ACHILLES will help create a sustainable impact on the field of hemato-oncology, advancing research, therapies, and ultimately the health outcomes of leukemia and lymphoma patients worldwide.

Официални данни · CORDIS · синхронизирано 17.10.2026 10:16 · официален запис · Лиценз: © European Union, CC BY 4.0 (Commission reuse policy).